Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

WASHINGTON, April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the prevention of vomiting in patients receiving glucagon-like peptide-1 (GLP-1) receptor agonist...